What Is Tranexamic Acid? How Did It Enter Dermatology?
Tranexamic acid (trans-4-aminomethylcyclohexane carboxylic acid) is a lysine analogue originally developed in the 1960s as an antifibrinolytic agent. While it had been used for decades in surgical haemostasis and menorrhagia management, its entry into dermatology began through a serendipitous observation: patients with melasma who were taking oral tranexamic acid showed marked generalised skin lightening, a finding documented in the scientific literature by Nijo and Kameyama in 1979.
Since then, tranexamic acid has risen to become one of the safest and most extensively studied agents targeting melanogenesis in both dermatological and medical aesthetic practice. It is used as an alternative or complement to hydroquinone-based protocols for stubborn pigmentation conditions such as pregnancy-related melasma, sun damage, and post-inflammatory hyperpigmentation.
Mechanisms by Which Tranexamic Acid Suppresses Melanogenesis
The effect of tranexamic acid in pigmentation treatment is achieved not through a single pathway but through multiple complementary mechanisms:
- Plasmin inhibition: Tranexamic acid blocks the conversion of plasminogen to plasmin. Plasmin normally triggers melanocyte activation via arachidonic acid and prostaglandins; this blockade indirectly reduces melanogenesis.
- Keratinocyte–melanocyte signal disruption: Under UV radiation, prostaglandin E2 and alpha-MSH produced by keratinocytes stimulate melanocytes to increase melanin synthesis. Tranexamic acid blocks this signalling, attenuating the epidermal UV response.
- Tyrosinase activity suppression (topical): When applied topically, tranexamic acid binds to the active site of the tyrosinase enzyme, competitively inhibiting L-DOPA conversion.
- Keratinocyte proliferation inhibition: It slows pigment distribution by reducing the turnover rate of melanin-transferring keratinocytes in the epidermis.
- Anti-inflammatory effect: In melasma cases with a vascular component, it reduces VEGF expression, thereby contributing to dermovascular hyperpigmentation.
Routes of Administration: Oral, Topical and Injectable Comparison
| Feature | Oral | Topical | Injectable (Meso) |
|---|---|---|---|
| Standard dose | 250 mg × 2/day | 2–5%, twice daily | 4–8 mg/cm², 4–6 sessions |
| Onset of effect | 4–8 weeks | 6–12 weeks | 2–4 sessions (rapid) |
| Melasma efficacy (MASI reduction) | 40–65% | 20–40% | 35–55% |
| Systemic absorption | High (systemic effect) | Low (local effect) | Moderate (dermis targeted) |
| Safety profile | Good; thrombosis risk should be monitored | Excellent | Very good; minimal bruising |
| Best suited for | Dermal + epidermal melasma | Epidermal spots, maintenance | Dermal melasma, PIH |
Oral Tranexamic Acid: Clinical Evidence and Protocol
Oral tranexamic acid has the strongest clinical evidence base among the routes of administration for melasma treatment. Randomised controlled trials have tested a broad dose range from 250 mg/day to 1,500 mg/day; the best safety-efficacy balance has been established at 500 mg/day (250 mg × 2).
A meta-analysis published in the Journal of the American Academy of Dermatology in 2022 (12 RCTs, 775 patients) demonstrated that oral tranexamic acid reduced the MASI score by an average of 49.2% compared with placebo, with efficacy comparable to 2% topical hydroquinone. Treatment duration is generally 8–12 weeks, and intermittent use (2 months on, 1 month off) is recommended for long-term maintenance.
Contraindications and safety monitoring: Oral tranexamic acid should not be used in patients with thrombophilic disease, a history of thrombosis, active oral contraceptive use, or during pregnancy and breastfeeding. With long-term use, a full blood count, coagulation tests, and if indicated lower-extremity venous Doppler evaluation are recommended at 3-month intervals.
Topical Tranexamic Acid: Formulations and Usage Guide
Topical tranexamic acid is available on the market in cream, serum, or toner forms at concentrations of 2–10%. The optimal clinical evidence supports the 2–5% range; there is insufficient data to confirm that higher concentrations provide additional efficacy.
Combination of topical tranexamic acid with other depigmenting agents creates powerful synergistic effects:
- Niacinamide (4–5%) + tranexamic acid (2%): The most commonly used combination, as it inhibits melanin transfer via two separate pathways.
- Retinoid + tranexamic acid: Accelerates keratinocyte turnover to support removal of pigment from the epidermis; evening application is recommended.
- Kojic acid + tranexamic acid: Dual blockade of tyrosinase inhibition; a powerful spot-treatment combination.
- Vitamin C (10–20%) combination: Antioxidant effect + melanin oxidation inhibition; stability issues may arise in the same formulation, so separate application is preferred.
Tranexamic Acid Injection via Mesotherapy
Intradermal tranexamic acid injection (mesotherapy) delivers the active compound directly to the vicinity of melanocytes in the dermis, bypassing the bloodstream and the epidermal barrier. This targeted approach offers a powerful strategy particularly in melasma with a predominant dermal component and in post-inflammatory hyperpigmentation (PIH).
The standard pigmentation mesotherapy protocol at Virtuana Clinic:
- Session frequency: Every 7–14 days, total 4–6 sessions
- Concentration: 5% tranexamic acid solution
- Technique: Nappage (papule) technique, 32G 4 mm needle, 0.02–0.05 mL per point
- Combined ingredients: Formulation synergy with glutathione, vitamin C, and hyaluronic acid
- Post-procedure care: No sun exposure for 24 hours after treatment; use of mineral-based SPF 50+
Tranexamic Acid in Melasma Treatment: MASI Score and Efficacy Data
The Melasma Area and Severity Index (MASI) is a standardised measure that assesses the surface distribution and pigment density of melasma on a scale of 0–48. Tranexamic acid's MASI performance across clinical studies is as follows:
| Study / Year | Route | Duration | MASI Reduction |
|---|---|---|---|
| Karn et al. (2012) | Oral 250 mg ×2 | 12 weeks | 48.7% |
| Taraz et al. (2017) | Oral vs. Topical 3% | 12 weeks | Oral 55% / Topical 35% |
| Lajevardi et al. (2021) | Intradermal meso | 6 sessions | 52.3% |
| JAAD Meta-analysis (2022) | Oral (pooled) | 8–16 weeks | 49.2% |
Use in Post-Inflammatory Hyperpigmentation (PIH)
Post-inflammatory hyperpigmentation is melanin accumulation arising after acne, laser treatment, chemical peeling, or mechanical trauma. It can be particularly pronounced and persistent in Fitzpatrick skin types III–VI. Tranexamic acid is effective in PIH treatment through the following mechanisms:
- It interrupts prostaglandin-mediated melanocyte activation triggered by the inflammatory reaction.
- It exerts an anti-inflammatory effect against pro-inflammatory cytokines secreted by damaged keratinocytes.
- In combination with niacinamide, it adds melanin transfer inhibition.
The preferred route for PIH is generally topical (2–5%) or a mesotherapy combination. Systemic treatment may be considered for cases covering very large surface areas.
Combination Protocols with Tranexamic Acid
Tranexamic acid produces synergistic effects when combined with other depigmenting agents and procedures. The most commonly applied combinations at Virtuana Clinic:
- Triple combination serum: Tranexamic acid + niacinamide + azelaic acid — broad-spectrum daily maintenance for melasma and PIH.
- Laser + oral tranexamic acid: Oral tranexamic acid before and after Q-switched Nd:YAG or picosecond laser treatment markedly reduces the risk of PIH and relapse.
- Chemical peel + mesotherapy: Surface renewal with mandelic acid or lactic acid peel followed by tranexamic acid mesotherapy to target deeper pigment.
- Retinoid + topical tranexamic acid: Retinoid at night, tranexamic acid in the morning — the most effective two-directional epidermal pigmentation treatment combination.
Sun Protection: The Indispensable Companion to Tranexamic Acid
No matter how potent tranexamic acid is, using it without sun protection dramatically reduces treatment efficacy. If UV radiation continues to activate melanocytes while melanogenesis is being suppressed, the net gain remains limited. For this reason, the following apply during tranexamic acid treatment:
- SPF 50+ broad-spectrum (UVA + UVB protection) is mandatory every morning.
- Mineral filters (zinc oxide, titanium dioxide) offer a less provocation-prone profile compared with chemical filters and are preferred in patients with melasma.
- Hats, sunglasses, and physical protection markedly enhance treatment efficacy.
- Cosmetic products should contain SPF, though they must not be used as a substitute for sunscreen.
Important Considerations When Using Tranexamic Acid
- With oral use, thrombosis risk factors (obesity, sedentary lifestyle, thrombophilic disease, oral contraceptive use) must always be assessed.
- Both oral and topical use are contraindicated during pregnancy and breastfeeding.
- Topical application may cause mild transient redness; this side effect resolves within 1–2 weeks.
- It should not be applied to damaged or actively inflamed skin.
- When used concurrently with a retinoid, a 30-minute interval between applications is recommended to reduce the risk of irritation.
Tranexamic Acid Pigmentation Treatment at Virtuana Clinic: Izmit and Kocaeli
At Virtuana Clinic, for presentations of melasma, PIH, and sun spots, we determine the pigmentation type (epidermal, dermal, or mixed) using Wood's lamp and clinical assessment, then design an individualised combination protocol based on tranexamic acid. The choice between oral, topical, and injectable options is made on the basis of Fitzpatrick skin type, lesion duration, individual risk factors, and the patient's treatment goals.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.